NCT05124275Phase 2Completed

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-09-06Actual

Enrollment · participants123Actual

Source updated2023-09-01Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Presbyopia

Treatments or interventions studied

Pilocarpine Ophthalmic Topical Cream, Dose 1DrugAlso known as GLK-302
Pilocarpine Ophthalmic Topical Cream, Dose 2DrugAlso known as GLK-302
Pilocarpine Ophthalmic Topical Cream, Dose 3DrugAlso known as GLK-302
Placebo Ophthalmic Topical CreamDrugAlso known as Placebo

Primary outcomes · main study measures

measure: Binocular Distance Corrected Near Visual Acuity (DCNVA); description: Proportion of treatment responders \[subjects gaining 3 lines or more in binocular distance corrected near visual acuity (DCNVA) and not losing more than 5 letters of binocular best corrected distance visual acuity (BCDVA)\] 1 hour post-dose at the Day 28 visit.; timeFrame: Day 28

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history